Antibodies to constant domains of therapeutic monoclonal antibodies: Anti-hinge antibodies in immunogenicity testing

Journal of Immunological Methods

Volumn 375, Issue 1-2, 2012, Pages 93-99

  Rispens, Theo ^a   de Vrieze, Henk ^b   de Groot, Els ^a   Wouters, Diana ^a   Stapel, Steven ^b   Wolbink, Gerrit J ^a,c   Aarden, Lucien A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c Reade   (Netherlands)

Author keywords

Adalimumab; Anti drug antibody (ADA); Epitope; Immunogenicity; Infliximab

Indexed keywords

ADALIMUMAB; ANTIBODY; DRUG ANTIBODY; HINGE ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G; INFLIXIMAB; RHEUMATOID FACTOR; RITUXIMAB; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOGENICITY; ISOTOPE LABELING; MAJOR CLINICAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC TESTS; PROTEIN STRUCTURE, TERTIARY; RHEUMATOID FACTOR;

EID: 84855351064     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2011.09.011     Document Type: Article

References (30)

1. Baert F., Noman M., Vermeire S., Van A.G., D' Haens G., Carbonez A., Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease N. Engl. J. Med. 2003, 348:601.
2. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S., Lems W.F., Aarden L., Dijkmans B.A., Tak P.P., Wolbink G.J. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 2007, 66:921.
3. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S.O., Lems W.F., Aarden L., Dijkmans B.A., Tak P.P., Wolbink G.J. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study. Ann. Rheum. Dis. 2009, 60:2541.
4. Bartelds G.M., de G.E., Nurmohamed M.T., Hart M.H., van Eede P.H., Wijbrandts C.A., Crusius J.B., Dijkmans B.A., Tak P.P., Aarden L., Wolbink G.J. Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study. Arthritis Res. Ther. 2010, 12:R221.
5. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., van Schouwenburg P.A., Lems W.F., Twisk J.W., Dijkmans B.A., Aarden L., Wolbink G.J. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305:1460.
6. Bendtzen K. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?. Arthritis Rheum. 2011, 63:867.
7. Bendtzen K., Geborek P., Svenson M., Larsson L., Kapetanovic M.C., Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006, 54:3782.
8. Ben-Horin S., Yavzori M., Katz L., Kopylov U., Picard O., Fudim E., Coscas D., Bar-Meir S., Goldstein I., Chowers Y. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011, 60:41.
9. Birdsall H.H., Lidsky M.D., Rossen R.D. Anti-Fab' antibodies in rheumatoid arthritis. Measurement of the relative quantities incorporated in soluble immune complexes in sera and supernatants from cultured peripheral blood lymphocytes. Arthritis Rheum. 1983, 26:1481.
10. Brezski R.J., Jordan R.E. Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity?. MAbs 2010, 2:212.
11. Brezski R.J., Luongo J.L., Petrone D., Ryan M.H., Zhong D., Tam S.H., Schmidt A.P., Kruszynski M., Whitaker B.P., Knight D.M., Jordan R.E. Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs. J. Immunol. 2008, 181:3183.
12. Fumia S., Goede J.S., Fischler M., Luginbuhl A., Frick S., Fodor P., Lutz H.U. Human F(ab')2-containing immune complexes together with anti-hinge natural antibodies stimulate complement amplification in vitro and in vivo. Mol. Immunol. 2008, 45:2951.
13. Hassan J., Feighery C., Bresnihan B., Whelan A. Prevalence of anti-Fab antibodies in patients with autoimmune and infectious diseases. Clin. Exp. Immunol. 1992, 89:423.
14. Jefferis R., Lefranc M.P. Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs 2009, 1:332.
15. Kosmac M., Avcin T., Toplak N., Simonini G., Cimaz R., Curin S.V. Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab. Pediatr. Res. 2011, 69:243.
16. Magdelaine-Beuzelin C., Vermeire S., Goodall M., Baert F., Noman M., Assche G.V., Ohresser M., Degenne D., Dugoujon J.M., Jefferis R., Rutgeerts P., Lefranc M.P., Watier H. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet. Genomics 2009, 19:383.
17. Mellbye O.J., Natvig J.B. Evidence for immune complexes containing antibody to the pepsin site of IgG in rheumatoid synovial fluids. Clin. Exp. Immunol. 1971, 8:889.
18. Osterland C.K., Harboe M., Kunkel H.G. Anti-gamma-globulin factors in human sera revealed by enzymatic splitting of anti-Rh antibodies. Vox Sang. 1963, 8:133.
19. Pascual-Salcedo D., Plasencia C., Ramiro S., Nuno L., Bonilla G., Nagore D., Ruiz Del A.A., Martinez A., Aarden L., Martin-Mola E., Balsa A. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 2011, 50:1445.
20. Persselin J.E., Stevens R.H. Anti-Fab antibodies in humans. Predominance of minor immunoglobulin G subclasses in rheumatoid arthritis. J. Clin. Invest. 1985, 76:723.
21. Persselin J.E., Keld B., Fried L., Stevens R.H. Subclasses of human IgG anti-Fab antibodies: parameters for optimum detection. Int. Arch. Allergy Appl. Immunol. 1985, 78:368.
22. Radstake T.R., Svenson M., Eijsbouts A.M., van den Hoogen F.H., Enevold C., Van Riel P.L., Bendtzen K. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann. Rheum. Dis. 2009, 68:1739.
23. Stickler M.M., Reddy A., Xiong J.M., Hinton P.R., DuBridge R., Harding F.A. The human G1m1 allotype associates with CD4+ T-cell responsiveness to a highly conserved IgG1 constant region peptide and confers an asparaginyl endopeptidase cleavage site. Genes Immun. 2011, 12:213.
24. Stubenrauch K., Wessels U., Vogel R., Schleypen J. Evaluation of a biosensor immunoassay for simultaneous characterization of isotype and binding region of human anti-tocilizumab antibodies with control by surrogate standards. Anal. Biochem. 2009, 390:189.
25. Susal C., Oberg H.H., Daniel V., Dorr C., Terness P., Huth-Kuhne A., Zimmermann R., Opelz G. Isotypes and IgG subclasses of anti-Fab antibodies in human immunodeficiency virus-infected hemophilia patients. Vox Sang. 1994, 66:37.
26. Tatarewicz S., Miller J.M., Swanson S.J., Moxness M.S. Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics. J. Immunol. Methods 2010, 357:10.
27. Terness P., Kohl I., Hubener G., Battistutta R., Moroder L., Welschof M., Dufter C., Finger M., Hain C., Jung M. The natural human IgG anti-F(ab')2 antibody recognizes a conformational IgG1 hinge epitope. J. Immunol. 1995, 154:6446.
28. Terness P., Navolan D., Moroder L., Siedler F., Weyher E., Kohl I., Dufter C., Welschof M., Drugarin D., Schneider F., Opelz G. A natural IgA-anti-F(ab')2gamma autoantibody occurring in healthy individuals and kidney graft recipients recognizes an IgG1 hinge region epitope. J. Immunol. 1996, 157:4251.
29. Vos G.H. Anti-fab' antibodies in human sera. I. A study of their distribution in health and disease. Vox Sang. 1977, 33:16.
30. Wolbink G.J., Vis M., Lems W., Voskuyl A.E., de G.E., Nurmohamed M.T., Stapel S., Tak P.P., Aarden L., Dijkmans B. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006, 54:711.